InflaRx (IFRX) said Wednesday it plans to discontinue further development of vilobelimab for the treatment of pyoderma gangrenosum, a rare and inflammatory skin disease.
An independent data monitoring committee conducting an unblinded interim analysis for a phase 3 trial for vilobelimab recommended that the trial be stopped due to futility, the company said.
InflaRx said it intends to focus its resources on INF904, with phase 2a data readouts in chronic spontaneous urticaria and hidradenitis suppurativa expected this summer.
The company said it is also contemplating additional cost savings and redirection of resources, with a view to extending its existing cash runway
InflaRx shares were down nearly 51% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。